Objective To observe the clinical effect of acupoint catgut embedding therapy on overweight or obese patients with type 2 diabetes mellitus. Methods 60 cases of overweight or obesity patients with type 2 diabetes mellitus were randomly divided into observation group and control group according to 1 ∶ 1. The control group was treated with oral metformin hydrochloride, and the observation group was treated with acupoint catgut embedding on the basis of the control group, once a week. Both groups were treated for 8 weeks, and followed up for 8 weeks after treatment. Fasting blood glucose(FBG), 2-hour postprandial blood glucose(PBG), glycosylated hemoglobin(HbAlc) and obesity were evaluated at week 0, week 8 and week 16, and the clinical efficacy was evaluated. Results ①The levels of FPG, PBG and HbAlc in the two groups were decreased at week 8 and 16 compared with week 0, and the observation group was better than the control group (P<0.05). ②The body mass index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR) of the two groups at 8 and 16 weeks were decreased compared with those at 0 weeks, and the BMI of the observation group was better than that of the control group(P<0.05). ③The incidence of adverse events in the two groups was lower, and the difference was not statistically significant(P>0.05). Conclusion Acupoint catgut embedding combined with metformin treatment can effectively improve the levels of FPG, PBG, HbAlc and reduce body weight in overweight or obesity patients with type 2 diabetes mellitus, with good safety and better efficacy than metformin alone.